Establishment of a reference material for standardization of the anti-complementary activity test in intravenous immunoglobulin products used in Japan: A collaborative study

Aggregates of human plasma-derived intravenous immunoglobulins (IVIGs) carries a risk of severe adverse events after nonspecific complement activation induced in humans administrated. Therefore, the anti-complementary activity (ACA) test is legally required in every batch of IVIGs in Japan. However,...

Full description

Saved in:
Bibliographic Details
Published inBiologicals Vol. 46; pp. 68 - 73
Main Authors Nojima, Kiyoko, Okuma, Kazu, Ochiai, Masaki, Kuramitsu, Madoka, Tezuka, Kenta, Ishii, Mieko, Ueda, Sadao, Miyamoto, Takashi, Kamimura, Koichiro, Kou, Enki, Uchida, Sanae, Watanabe, Yoshiharu, Okada, Yoshiaki, Hamaguchi, Isao
Format Journal Article
LanguageEnglish
Published England Elsevier Ltd 01.03.2017
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Aggregates of human plasma-derived intravenous immunoglobulins (IVIGs) carries a risk of severe adverse events after nonspecific complement activation induced in humans administrated. Therefore, the anti-complementary activity (ACA) test is legally required in every batch of IVIGs in Japan. However, due to the intrinsic nature of this bioassay, there might be large differences in the results of ACA tests from laboratories, even when the same batch of IVIGs was measured. Our six laboratories evaluated whether there were such differences and argued for establishment of a reference material (RM) for standardization of the ACA test. Our results revealed inter-laboratory differences in ACA values, indicating a need to establish an RM. Therefore, after ACA values in candidate RMs were measured collaboratively, one RM was selected from two candidates and unit value-assigned. The RM in fact normalized the ACA test values for samples measured in parallel at almost all the laboratories, when the values were calculated relative to the assigned unit value of the RM. Thus, we established a first RM to standardize the ACA test in Japan, which enabled each laboratory to normalize ACA values constantly for IVIGs. This indicates that the establishment of an RM can contribute to quality control of IVIGs.
AbstractList Aggregates of human plasma-derived intravenous immunoglobulins (IVIGs) carries a risk of severe adverse events after nonspecific complement activation induced in humans administrated. Therefore, the anti-complementary activity (ACA) test is legally required in every batch of IVIGs in Japan. However, due to the intrinsic nature of this bioassay, there might be large differences in the results of ACA tests from laboratories, even when the same batch of IVIGs was measured. Our six laboratories evaluated whether there were such differences and argued for establishment of a reference material (RM) for standardization of the ACA test. Our results revealed inter-laboratory differences in ACA values, indicating a need to establish an RM. Therefore, after ACA values in candidate RMs were measured collaboratively, one RM was selected from two candidates and unit value-assigned. The RM in fact normalized the ACA test values for samples measured in parallel at almost all the laboratories, when the values were calculated relative to the assigned unit value of the RM. Thus, we established a first RM to standardize the ACA test in Japan, which enabled each laboratory to normalize ACA values constantly for IVIGs. This indicates that the establishment of an RM can contribute to quality control of IVIGs.
Aggregates of human plasma-derived intravenous immunoglobulins (IVIGs) carries a risk of severe adverse events after nonspecific complement activation induced in humans administrated. Therefore, the anti-complementary activity (ACA) test is legally required in every batch of IVIGs in Japan. However, due to the intrinsic nature of this bioassay, there might be large differences in the results of ACA tests from laboratories, even when the same batch of IVIGs was measured. Our six laboratories evaluated whether there were such differences and argued for establishment of a reference material (RM) for standardization of the ACA test. Our results revealed inter-laboratory differences in ACA values, indicating a need to establish an RM. Therefore, after ACA values in candidate RMs were measured collaboratively, one RM was selected from two candidates and unit value-assigned. The RM in fact normalized the ACA test values for samples measured in parallel at almost all the laboratories, when the values were calculated relative to the assigned unit value of the RM. Thus, we established a first RM to standardize the ACA test in Japan, which enabled each laboratory to normalize ACA values constantly for IVIGs. This indicates that the establishment of an RM can contribute to quality control of IVIGs.Aggregates of human plasma-derived intravenous immunoglobulins (IVIGs) carries a risk of severe adverse events after nonspecific complement activation induced in humans administrated. Therefore, the anti-complementary activity (ACA) test is legally required in every batch of IVIGs in Japan. However, due to the intrinsic nature of this bioassay, there might be large differences in the results of ACA tests from laboratories, even when the same batch of IVIGs was measured. Our six laboratories evaluated whether there were such differences and argued for establishment of a reference material (RM) for standardization of the ACA test. Our results revealed inter-laboratory differences in ACA values, indicating a need to establish an RM. Therefore, after ACA values in candidate RMs were measured collaboratively, one RM was selected from two candidates and unit value-assigned. The RM in fact normalized the ACA test values for samples measured in parallel at almost all the laboratories, when the values were calculated relative to the assigned unit value of the RM. Thus, we established a first RM to standardize the ACA test in Japan, which enabled each laboratory to normalize ACA values constantly for IVIGs. This indicates that the establishment of an RM can contribute to quality control of IVIGs.
Author Ueda, Sadao
Miyamoto, Takashi
Tezuka, Kenta
Nojima, Kiyoko
Kamimura, Koichiro
Kou, Enki
Uchida, Sanae
Hamaguchi, Isao
Kuramitsu, Madoka
Okuma, Kazu
Ochiai, Masaki
Ishii, Mieko
Watanabe, Yoshiharu
Okada, Yoshiaki
Author_xml – sequence: 1
  givenname: Kiyoko
  surname: Nojima
  fullname: Nojima, Kiyoko
  organization: Department of Safety Research on Blood and Biological Products, National Institute of Infectious Diseases, Musashimurayama, Tokyo 208-0011, Japan
– sequence: 2
  givenname: Kazu
  surname: Okuma
  fullname: Okuma, Kazu
  organization: Department of Safety Research on Blood and Biological Products, National Institute of Infectious Diseases, Musashimurayama, Tokyo 208-0011, Japan
– sequence: 3
  givenname: Masaki
  surname: Ochiai
  fullname: Ochiai, Masaki
  organization: Department of Quality Assurance and Radiological Protection, National Institute of Infectious Diseases, Musashimurayama, Tokyo 208-0011, Japan
– sequence: 4
  givenname: Madoka
  surname: Kuramitsu
  fullname: Kuramitsu, Madoka
  organization: Department of Safety Research on Blood and Biological Products, National Institute of Infectious Diseases, Musashimurayama, Tokyo 208-0011, Japan
– sequence: 5
  givenname: Kenta
  surname: Tezuka
  fullname: Tezuka, Kenta
  organization: Department of Safety Research on Blood and Biological Products, National Institute of Infectious Diseases, Musashimurayama, Tokyo 208-0011, Japan
– sequence: 6
  givenname: Mieko
  surname: Ishii
  fullname: Ishii, Mieko
  organization: Department of Safety Research on Blood and Biological Products, National Institute of Infectious Diseases, Musashimurayama, Tokyo 208-0011, Japan
– sequence: 7
  givenname: Sadao
  surname: Ueda
  fullname: Ueda, Sadao
  organization: Japan Blood Products Organization, Fukuchiyama, Kyoto 620-0853, Japan
– sequence: 8
  givenname: Takashi
  surname: Miyamoto
  fullname: Miyamoto, Takashi
  organization: Japan Blood Products Organization, Fukuchiyama, Kyoto 620-0853, Japan
– sequence: 9
  givenname: Koichiro
  surname: Kamimura
  fullname: Kamimura, Koichiro
  organization: The Chemo-Sero-Therapeutic Research Institute, Kumamoto, Kumamoto 860-8568, Japan
– sequence: 10
  givenname: Enki
  surname: Kou
  fullname: Kou, Enki
  organization: Nihon Pharmaceutical Co. Ltd., Narita, Chiba 286-0825, Japan
– sequence: 11
  givenname: Sanae
  surname: Uchida
  fullname: Uchida, Sanae
  organization: CSL Behring K.K., Yashio, Saitama 340-0833, Japan
– sequence: 12
  givenname: Yoshiharu
  surname: Watanabe
  fullname: Watanabe, Yoshiharu
  organization: Baxter Limited, Chuo-ku, Tokyo 104-6009, Japan
– sequence: 13
  givenname: Yoshiaki
  surname: Okada
  fullname: Okada, Yoshiaki
  organization: Department of Safety Research on Blood and Biological Products, National Institute of Infectious Diseases, Musashimurayama, Tokyo 208-0011, Japan
– sequence: 14
  givenname: Isao
  surname: Hamaguchi
  fullname: Hamaguchi, Isao
  email: 130hama@niid.go.jp
  organization: Department of Safety Research on Blood and Biological Products, National Institute of Infectious Diseases, Musashimurayama, Tokyo 208-0011, Japan
BackLink https://www.ncbi.nlm.nih.gov/pubmed/28162840$$D View this record in MEDLINE/PubMed
BookMark eNqNkl1vFCEUhompsR_6FwzeeTMrMDPMrDem2dRW08QbvSYMnGnZMLACs8n2P_kfPeNWY7yxCckh8PCej5dzchJiAELecLbijMt329Xgoo93zmifVwKPVlysGOufkTPO1m3V14KdLPumrThr5Sk5z3nLGOdN17wgp6LnUvQNOyM_rnLRg3f5foJQaByppglGSBAM0EkXSE57OsZEEQxWJ-sedHExLGy5B6pDcZWJ087DIqHTgWpT3N6VAy2QC3UBV0l6DyHOmbppmkO883GYPV7tUrSzKZnOGezCftY7Hd7TS2qi93qICbPtAbPP9vCSPB-xZXj1GC_It49XXzc31e2X60-by9vKNJ0slbSdluvamq7F2EMvOt0Z1ozCtNJq3ZoRB1ELbXVbd7bvbN0yaZuBc95bIeoL8vaoi9V9n7EJNblsAOsJgD0owRirZS1581-U97JtaynYGtHXj-g8TGDVLrkJx6V-u4HA-giYFHNGG_4gnKnFebVVfzmvFucVFwqdx7cf_nlrXPllFI7e-ScpbI4KgJPdO0gqG7d8A-sSmKJsdE9Q-QkTE9aX
CitedBy_id crossref_primary_10_24171_j_phrp_2018_9_3_10
Cites_doi 10.1111/j.1423-0410.2009.01271.x
10.1111/j.1423-0410.1962.tb03240.x
10.4049/jimmunol.156.2.749
10.1016/j.biologicals.2010.11.002
10.1111/j.1423-0410.1975.tb00485.x
10.1006/biol.1996.0063
ContentType Journal Article
Copyright 2017 International Alliance for Biological Standardization
Copyright © 2017 International Alliance for Biological Standardization. Published by Elsevier Ltd. All rights reserved.
Copyright_xml – notice: 2017 International Alliance for Biological Standardization
– notice: Copyright © 2017 International Alliance for Biological Standardization. Published by Elsevier Ltd. All rights reserved.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
7S9
L.6
DOI 10.1016/j.biologicals.2016.12.008
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
AGRICOLA
AGRICOLA - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
AGRICOLA
AGRICOLA - Academic
DatabaseTitleList MEDLINE

AGRICOLA
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 1095-8320
EndPage 73
ExternalDocumentID 28162840
10_1016_j_biologicals_2016_12_008
S1045105616301683
Genre Journal Article
GeographicLocations Japan
GeographicLocations_xml – name: Japan
GroupedDBID ---
--K
--M
.~1
0R~
1B1
1RT
1~.
1~5
23N
4.4
457
4G.
53G
5GY
5VS
6J9
7-5
71M
8P~
9JM
AAAJQ
AACTN
AAEDT
AAEDW
AAIAV
AAIKJ
AAKOC
AALRI
AAOAW
AAQFI
AAQXK
AARKO
AAXUO
ABBQC
ABFNM
ABFRF
ABGSF
ABJNI
ABLVK
ABMAC
ABMZM
ABUDA
ABXDB
ABYKQ
ACDAQ
ACGFO
ACGFS
ACRLP
ADBBV
ADEZE
ADFGL
ADMUD
ADUVX
AEBSH
AEFWE
AEHWI
AEKER
AENEX
AFKWA
AFTJW
AFXIZ
AGEKW
AGHFR
AGRDE
AGUBO
AGYEJ
AHHHB
AIEXJ
AIKHN
AITUG
AJBFU
AJOXV
AJRQY
ALMA_UNASSIGNED_HOLDINGS
AMFUW
AMRAJ
ANZVX
ASPBG
AVWKF
AXJTR
AZFZN
BKOJK
BLXMC
BNPGV
CAG
CJTIS
COF
CS3
DM4
DOVZS
DU5
EBS
EFBJH
EFLBG
EJD
EO8
EO9
EP2
EP3
F5P
FDB
FEDTE
FGOYB
FIRID
FNPLU
FYGXN
G-2
G-Q
GBLVA
HEJ
HMG
HMK
HMO
HVGLF
HZ~
IHE
J1W
KOM
LCYCR
LG5
LUGTX
LZ5
M29
M41
MO0
N9A
O-L
O9-
OAUVE
OZT
P-8
P-9
P2P
PC.
Q38
R2-
RIG
ROL
RPZ
SAE
SDF
SDG
SDP
SES
SEW
SIN
SPCBC
SSH
SSI
SSU
SSZ
T5K
UNMZH
WUQ
XPP
ZMT
~G-
~KM
AAHBH
AATTM
AAXKI
AAYWO
AAYXX
ABWVN
ACIEU
ACRPL
ACVFH
ADCNI
ADNMO
AEIPS
AEUPX
AFJKZ
AFPUW
AGCQF
AGQPQ
AGRNS
AIGII
AIIUN
AKBMS
AKRWK
AKYEP
ANKPU
APXCP
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
7S9
L.6
ID FETCH-LOGICAL-c476t-6d7a693dc75a698e827a7c04f2c56daa5cf14732ada537d87d3506d4b1118d223
IEDL.DBID .~1
ISSN 1045-1056
1095-8320
IngestDate Fri Jul 11 00:15:17 EDT 2025
Fri Jul 11 03:27:59 EDT 2025
Mon May 19 03:31:22 EDT 2025
Thu Apr 24 22:54:44 EDT 2025
Tue Jul 01 03:56:49 EDT 2025
Fri Feb 23 02:34:22 EST 2024
IsPeerReviewed true
IsScholarly true
Keywords Reference material
Anti-complementary activity
Standardization
Language English
License Copyright © 2017 International Alliance for Biological Standardization. Published by Elsevier Ltd. All rights reserved.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c476t-6d7a693dc75a698e827a7c04f2c56daa5cf14732ada537d87d3506d4b1118d223
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
PMID 28162840
PQID 1865536209
PQPubID 23479
PageCount 6
ParticipantIDs proquest_miscellaneous_2000363614
proquest_miscellaneous_1865536209
pubmed_primary_28162840
crossref_primary_10_1016_j_biologicals_2016_12_008
crossref_citationtrail_10_1016_j_biologicals_2016_12_008
elsevier_sciencedirect_doi_10_1016_j_biologicals_2016_12_008
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate March 2017
2017-03-00
2017-Mar
20170301
PublicationDateYYYYMMDD 2017-03-01
PublicationDate_xml – month: 03
  year: 2017
  text: March 2017
PublicationDecade 2010
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle Biologicals
PublicationTitleAlternate Biologicals
PublicationYear 2017
Publisher Elsevier Ltd
Publisher_xml – name: Elsevier Ltd
References Barandun, Kistler, Jeunet, Isliker (bib1) 1962; 7
Mayer (bib9) 1961
Kotitschke, Harbauer (bib4) 1992; 19
Miletic, Hester, Frank (bib3) 1996; 156
Georgakopoulos, Tatford, Gurevich, Bertolini (bib14) 2011; 39
(bib11) 2006
Buchacher, Schluga, Müllner, Schreiner, Kannicht, Weinberger (bib8) 2010; 98
European Pharmacopoeia 8th Edition. 2.6.17. Test for anticomplementary activity (ACA) of immunoglobulin for intravenous administration, 200–2.
Ramasamy, Tran, Farrugia (bib2) 1997; 25
Kistler, Steiger (bib13) 1970; 4
Rousell, Budinger, Keppler, Victor, Minaga (bib6) 1989; 11
(bib7) 2006
Miekka, Gozze (bib5) 1975; 29
Sandberg, Daas, Behr-Gross (bib12) 2006; 1
Georgakopoulos (10.1016/j.biologicals.2016.12.008_bib14) 2011; 39
Miekka (10.1016/j.biologicals.2016.12.008_bib5) 1975; 29
Barandun (10.1016/j.biologicals.2016.12.008_bib1) 1962; 7
Buchacher (10.1016/j.biologicals.2016.12.008_bib8) 2010; 98
Mayer (10.1016/j.biologicals.2016.12.008_bib9) 1961
Ramasamy (10.1016/j.biologicals.2016.12.008_bib2) 1997; 25
Miletic (10.1016/j.biologicals.2016.12.008_bib3) 1996; 156
10.1016/j.biologicals.2016.12.008_bib10
Kotitschke (10.1016/j.biologicals.2016.12.008_bib4) 1992; 19
Sandberg (10.1016/j.biologicals.2016.12.008_bib12) 2006; 1
(10.1016/j.biologicals.2016.12.008_bib11) 2006
Kistler (10.1016/j.biologicals.2016.12.008_bib13) 1970; 4
(10.1016/j.biologicals.2016.12.008_bib7) 2006
Rousell (10.1016/j.biologicals.2016.12.008_bib6) 1989; 11
References_xml – volume: 25
  start-page: 87
  year: 1997
  end-page: 92
  ident: bib2
  article-title: Measurement of anticomplementary activity in therapeutic intravenous immunoglobulin preparations
  publication-title: Biologicals
– volume: 156
  start-page: 749
  year: 1996
  end-page: 757
  ident: bib3
  article-title: Regulation of complement activity by immunoglobulin. I. Effect of immunoglobulin isotype on C4 uptake on antibody-sensitized sheep erythrocytes and solid phase immune complexes
  publication-title: J Immunol
– volume: 11
  start-page: 143
  year: 1989
  end-page: 150
  ident: bib6
  article-title: Anticomplementary activity and the safety of intravenous immunoglobulin
  publication-title: Clin Ther
– volume: 7
  start-page: 157
  year: 1962
  end-page: 174
  ident: bib1
  article-title: Intravenous administration of human gamma-globulin
  publication-title: Vox Sang
– volume: 4
  start-page: 92
  year: 1970
  end-page: 94
  ident: bib13
  article-title: Human immunoglobulins for intravenous administration: preparation and properties
  publication-title: Progr Immunobiol Stand
– volume: 39
  start-page: 38
  year: 2011
  end-page: 42
  ident: bib14
  article-title: C1q aggregate binding for the determination of anti-complementary activity of immunoglobulin products
  publication-title: Biologicals
– volume: 98
  start-page: e209
  year: 2010
  end-page: e218
  ident: bib8
  article-title: Anticomplementary activity of IVIG concentrates – important assay parameters and impact of IgG polymers
  publication-title: Vox Sang
– start-page: 288
  year: 2006
  ident: bib7
  publication-title: Minimum Requirements for biological products. Test for freedom from anti-complement activity
– volume: 1
  start-page: 37
  year: 2006
  end-page: 48
  ident: bib12
  article-title: Collaborative study to establish human immunoglobulin BRP batch 3 and human immunoglobulin (molecular size) BRP batch 1
  publication-title: Pharmeuropa Bio
– volume: 19
  start-page: 23
  year: 1992
  end-page: 28
  ident: bib4
  article-title: Safety tests of the intravenous tolerance of immunoglobulins. Multicenter study of the section ‘blood plasma constituents’ of the German association of transfusion medicine and immunohematology (DGTI)
  publication-title: Infusionsther Transfusionsmed
– year: 2006
  ident: bib11
  publication-title: Recommendations for the preparation, characterization and establishment of international and other biological reference standards (revised 2004)
– start-page: 133
  year: 1961
  end-page: 240
  ident: bib9
  article-title: Complement and complement fixation
  publication-title: Experimental immunochemistry
– volume: 29
  start-page: 101
  year: 1975
  end-page: 123
  ident: bib5
  article-title: Anticomplementary activity of human immunoglobulin G. I. Mechanism of the artifactual increase in anticomplementary activity of IgG during the assay
  publication-title: Vox Sang
– reference: European Pharmacopoeia 8th Edition. 2.6.17. Test for anticomplementary activity (ACA) of immunoglobulin for intravenous administration, 200–2.
– ident: 10.1016/j.biologicals.2016.12.008_bib10
– volume: 1
  start-page: 37
  year: 2006
  ident: 10.1016/j.biologicals.2016.12.008_bib12
  article-title: Collaborative study to establish human immunoglobulin BRP batch 3 and human immunoglobulin (molecular size) BRP batch 1
  publication-title: Pharmeuropa Bio
– start-page: 133
  year: 1961
  ident: 10.1016/j.biologicals.2016.12.008_bib9
  article-title: Complement and complement fixation
– volume: 4
  start-page: 92
  year: 1970
  ident: 10.1016/j.biologicals.2016.12.008_bib13
  article-title: Human immunoglobulins for intravenous administration: preparation and properties
  publication-title: Progr Immunobiol Stand
– volume: 98
  start-page: e209
  year: 2010
  ident: 10.1016/j.biologicals.2016.12.008_bib8
  article-title: Anticomplementary activity of IVIG concentrates – important assay parameters and impact of IgG polymers
  publication-title: Vox Sang
  doi: 10.1111/j.1423-0410.2009.01271.x
– volume: 7
  start-page: 157
  year: 1962
  ident: 10.1016/j.biologicals.2016.12.008_bib1
  article-title: Intravenous administration of human gamma-globulin
  publication-title: Vox Sang
  doi: 10.1111/j.1423-0410.1962.tb03240.x
– volume: 19
  start-page: 23
  year: 1992
  ident: 10.1016/j.biologicals.2016.12.008_bib4
  article-title: Safety tests of the intravenous tolerance of immunoglobulins. Multicenter study of the section ‘blood plasma constituents’ of the German association of transfusion medicine and immunohematology (DGTI)
  publication-title: Infusionsther Transfusionsmed
– year: 2006
  ident: 10.1016/j.biologicals.2016.12.008_bib11
– volume: 156
  start-page: 749
  year: 1996
  ident: 10.1016/j.biologicals.2016.12.008_bib3
  article-title: Regulation of complement activity by immunoglobulin. I. Effect of immunoglobulin isotype on C4 uptake on antibody-sensitized sheep erythrocytes and solid phase immune complexes
  publication-title: J Immunol
  doi: 10.4049/jimmunol.156.2.749
– volume: 11
  start-page: 143
  year: 1989
  ident: 10.1016/j.biologicals.2016.12.008_bib6
  article-title: Anticomplementary activity and the safety of intravenous immunoglobulin
  publication-title: Clin Ther
– volume: 39
  start-page: 38
  year: 2011
  ident: 10.1016/j.biologicals.2016.12.008_bib14
  article-title: C1q aggregate binding for the determination of anti-complementary activity of immunoglobulin products
  publication-title: Biologicals
  doi: 10.1016/j.biologicals.2010.11.002
– start-page: 288
  year: 2006
  ident: 10.1016/j.biologicals.2016.12.008_bib7
– volume: 29
  start-page: 101
  year: 1975
  ident: 10.1016/j.biologicals.2016.12.008_bib5
  article-title: Anticomplementary activity of human immunoglobulin G. I. Mechanism of the artifactual increase in anticomplementary activity of IgG during the assay
  publication-title: Vox Sang
  doi: 10.1111/j.1423-0410.1975.tb00485.x
– volume: 25
  start-page: 87
  year: 1997
  ident: 10.1016/j.biologicals.2016.12.008_bib2
  article-title: Measurement of anticomplementary activity in therapeutic intravenous immunoglobulin preparations
  publication-title: Biologicals
  doi: 10.1006/biol.1996.0063
SSID ssj0011474
Score 2.099302
Snippet Aggregates of human plasma-derived intravenous immunoglobulins (IVIGs) carries a risk of severe adverse events after nonspecific complement activation induced...
SourceID proquest
pubmed
crossref
elsevier
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 68
SubjectTerms Animals
Anti-complementary activity
bioassays
Biological Assay - methods
Biological Assay - standards
Calibration
complement
Complement Activation - drug effects
Complement Inactivating Agents - pharmacology
Complement Inactivating Agents - standards
Cooperative Behavior
Guinea Pigs
Humans
immunoglobulins
Immunoglobulins, Intravenous - pharmacology
Immunoglobulins, Intravenous - standards
intravenous injection
Japan
Laboratories - standards
Quality Control
Reference material
Reference Standards
Reproducibility of Results
risk
Sheep
Standardization
Title Establishment of a reference material for standardization of the anti-complementary activity test in intravenous immunoglobulin products used in Japan: A collaborative study
URI https://dx.doi.org/10.1016/j.biologicals.2016.12.008
https://www.ncbi.nlm.nih.gov/pubmed/28162840
https://www.proquest.com/docview/1865536209
https://www.proquest.com/docview/2000363614
Volume 46
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1La9wwEBYhoaWXkr43TcMEenXXlq2HSy7LkrBN21DaBnITsiSDQ_EuiVPIJf-o_7Ezsr1NoYFAwSAwIxAzo9FneeYbxt6mpVNVLi1-5AieFDV-s1aC-6QUjldlnesqtk74fCIXp8XxmTjbYPOxFobSKofY38f0GK2HN9NBm9NV00y_ZUSNQgBYopNKTYyfRaHIy9_drNM8EO5HJmYSTkj6Idv_k-PVEx2RNoi5O5PxZpA6Tf77jLoLg8az6GibPR5AJMz6dT5hG6F9yh70bSWvn7Ffhwj54u0SXf3BsgYL63YigBA1eh0gXIXxJmGoxiRZRISA6m6SmG3eJ5dfXAMVQFCfCUBs2kHT4tNR6yKieIWGqkyWRC5Cie2w6mlkL-HqMniSPcYjuX0PM7jldj8DRG7b5-z06PD7fJEMbRkSh-rtEumVlWXunRI46qC5ssqlRc2dkN5a4WpUes6ttyJXXiufi1T6osKwqj3CkRdss1224RUDV-rCVyEPJbFW2tKqPIQKbWlTX6d1PWF6NIRxA2c5tc74YcbktHNzy4aGbGgybtCGE8bXU1c9ccd9Jh2M1jZ_eaHBA-Y-0_dHDzG4S-nXi20DmsFkVP-LWCEt75bhkRwoR7w0YS9791qvnOtMIpBId_5vga_ZI06wJObQ7bLN7uIqvEFQ1VV7cdfssa3Z_OunLzR--Lg4-Q0QqCkZ
linkProvider Elsevier
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1La9wwEBYhoY9L6bvb5wTao7u2bD0c2kNoEzbPSxPITZUtGVyKd8k6DXvpP-qpfzAzsr1NoYFACRgMRgKhGY0-yTPfx9jbOC9VkUqLhxzBo6zCM2shuItyUfIir1JdBOmEg0M5Oc52T8TJCvs91MJQWmUf-7uYHqJ1_2Xcz-Z4VtfjLwlRoxAAluikUg8K1nt-cY7ntvnHnc9o5Hecb28dfZpEvbRAVGZKtpF0yso8daUS-NZec2VVGWcVL4V01oqySjKVcuusSJXTyqUili4rMDRox4ntAOP-WobhgmQT3v9c5pXg-SJQP9PoIhrebbb-J6msY1ai6Seq8ESGq0iStvz3pngV6A2b3_Z9dq9HrbDZTcwDtuKbh-xWp2O5eMR-bSHGDNdZdNcI0wosLPVLADFxcHNAfAzD1UVf_kltEYIC2reOQnp7l81-ugCquCBhC0Aw3ELd4NOSVhJxykJNZS1TYjOhTHqYdby1czibe0dtdxEDNBuwCZf8_IeHQKb7mB3fiLGesNVm2vhnDMpcZ67wqc-JJtPmVqXeF-g8NnZVXFUjpgdDmLInSSetju9myIb7Zi7Z0JANTcIN2nDE-LLrrGMKuU6nD4O1zV9ub3BHu0739cFDDIYF-tdjG49mMAkVHCM4ifOr2_DARpQiQBuxp517LUfOdSIRucTP_2-Ab9idydHBvtnfOdx7we5ywkQhge8lW21Pz_wrRHRt8TqsIGBfb3rJXgDxHmKW
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Establishment+of+a+reference+material+for+standardization+of+the+anti-complementary+activity+test+in+intravenous+immunoglobulin+products+used+in+Japan%3A+A+collaborative+study&rft.jtitle=Biologicals&rft.au=Nojima%2C+Kiyoko&rft.au=Okuma%2C+Kazu&rft.au=Ochiai%2C+Masaki&rft.au=Kuramitsu%2C+Madoka&rft.date=2017-03-01&rft.issn=1045-1056&rft.volume=46&rft.spage=68&rft.epage=73&rft_id=info:doi/10.1016%2Fj.biologicals.2016.12.008&rft.externalDBID=n%2Fa&rft.externalDocID=10_1016_j_biologicals_2016_12_008
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1045-1056&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1045-1056&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1045-1056&client=summon